Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies with immunology ideas popularized by cancer fighters, is launching under the leadership of departing Biogen Inc. CEO George Scangos. Robert Nelsen, whose Arch Venture Partners is leading a $150 million investment with additional funds coming from the Bill & Melinda Gates Foundation.